Neurology

Message from the National MS Society: We are closely watching the coronavirus (COVID-19) situation and taking action as we all move through this uncharted territory. The most recent guidance from the Centers for Disease Control and Prevention (CDC) about in-person gatherings has a significant impact on all we had planned for the next couple months—from...

A new study is claiming that neurological decline in patients with multiple sclerosis (MS) may not be as inevitable as previously thought. The study, “A longitudinal study of cognitive function in multiple sclerosis: is decline inevitable?,” was published in the Journal of Neurology. For many years, statistics have implied that some kind of cognitive impairment affects...

Latinx and Black multiple sclerosis (MS) patients have a higher number of disease-associated antibody-secreting cells in their blood compared to those who identify as Caucasian, a new U.S. study reports. This new evidence may kickstart a myriad of unique treatments for MS based on genetic and ethnic differences. The study, “Black African and Latino/a identity...

According to a study published in the July edition of the Neurology journal in 2007, multiple sclerosis affects the immune systems of African-Americans and whites differently.  The study, pointed out that multiple sclerosis (MS) is not as prevalent but often more severe in Black people than in whites. The exact reason still hasn’t been identified,...

A recent study suggests that there may be a link between MS progression and blood lipids in MS patients who are overweight or obese.  The study  published in the Lancet journal EBioMedicine supports previous research that hints food, diet, and exercise can help affect disease progression in MS patients. The study was conducted by researchers at the...

Most of the latest Multiple Sclerosis treatments cater to relapsing and remitting MS patients. Until Roche’s blockbuster drug Ocrevus launched for progressive MS, patients with progressive and advanced multiple sclerosis had not benefitted as much from therapeutic innovations in the MS space. Renowned neurologist, Robert Fox indicates that he always is very transparent with newly...

Multiple sclerosis (MS) is an immune-mediated progressive disease that results in chronic inflammation and demyelination of the central nervous system. It leads to physical and cognitive disability, with symptoms including fatigue, gait and visual disturbances, bowl and bladder dysfunction, cognitive dysfunction and mental health symptoms. The exact cause of MS is unknown but is thought to...

Multiple sclerosis affects approximately 400,000 people across the United States and over 2 million people worldwide. [Munoz-Culla 2013; Buchanan 2011] Symptoms of MS include focal signs such as weak motor and sensory deficits, visual disorders, spasticity, bladder and bowel dysfunction, and dysphagia, as well as generalized symptoms, including depression, pain, cognitive difficulties, and fatigue. [Kahn...

A lack of diverse representation of patients in clinical research has made it difficult to adequately assess the unique patient journey and efficacy of treatment for minority MS patients in comparison to non-Hispanic Caucasian women.   According to a recent study published earlier this year in Multiple Sclerosis and Demyelinating Disorders. The African-American population in...